Home / Articles / Structure and biological activity of endogenous and synthetic agonists of GPR119

Structure and biological activity of endogenous and synthetic agonists of GPR119

Ivan Nikolaevich Tyurenkov 1
Ivan Nikolaevich Tyurenkov
, 
Alexander Alexandrovich Ozerov 1
Alexander Alexandrovich Ozerov
, 
Denis Vladimirovich Kurkin 1
Denis Vladimirovich Kurkin
, 
Ekaterina Olegovna Logvinova 1
Ekaterina Olegovna Logvinova
, 
Dmitry Aleksandrovich Bakulin 1
Dmitry Aleksandrovich Bakulin
, 
Elena Vladimirovna Volotova 1
Elena Vladimirovna Volotova
, 
Dmitry Dmitrievich Borodin 1
Dmitry Dmitrievich Borodin
1 Volgograd State Medical University
10.1070/RCR4737
Published 30 November 2017
Review , RCR4737, Volume 87, Issue 2, 151-166
8
Share
Cite this
GOST
 | 
Cite this
GOST
Copy cite
Tyurenkov I. N. et al. Structure and biological activity of endogenous and synthetic agonists of GPR119 // Russian Chemical Reviews. 2017. Vol. 87. No. 2. pp. 151-166.
GOST all authors (up to 50)
Copy cite
Tyurenkov I. N., Ozerov A. A., Kurkin D. V., Logvinova E. O., Bakulin D. A., Volotova E. V., Borodin D. D. Structure and biological activity of endogenous and synthetic agonists of GPR119 // Russian Chemical Reviews. 2017. Vol. 87. No. 2. pp. 151-166.
RIS
 | 
Cite this
RIS
Copy cite
TY - JOUR
DO - 10.1070/RCR4737
UR - https://rcr.colab.ws/publications/10.1070/RCR4737
TI - Structure and biological activity of endogenous and synthetic agonists of GPR119
T2 - Russian Chemical Reviews
AU - Tyurenkov, Ivan Nikolaevich
AU - Ozerov, Alexander Alexandrovich
AU - Kurkin, Denis Vladimirovich
AU - Logvinova, Ekaterina Olegovna
AU - Bakulin, Dmitry Aleksandrovich
AU - Volotova, Elena Vladimirovna
AU - Borodin, Dmitry Dmitrievich
PY - 2017
DA - 2017/11/30
PB - ANO Editorial Board of the journal Uspekhi Khimii
SP - 151-166
IS - 2
VL - 87
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors)
Copy cite
@article{2017_Tyurenkov,
author = {Ivan Nikolaevich Tyurenkov and Alexander Alexandrovich Ozerov and Denis Vladimirovich Kurkin and Ekaterina Olegovna Logvinova and Dmitry Aleksandrovich Bakulin and Elena Vladimirovna Volotova and Dmitry Dmitrievich Borodin},
title = {Structure and biological activity of endogenous and synthetic agonists of GPR119},
journal = {Russian Chemical Reviews},
year = {2017},
volume = {87},
publisher = {ANO Editorial Board of the journal Uspekhi Khimii},
month = {Nov},
url = {https://rcr.colab.ws/publications/10.1070/RCR4737},
number = {2},
pages = {151--166},
doi = {10.1070/RCR4737}
}
MLA
Cite this
MLA
Copy cite
Tyurenkov, Ivan Nikolaevich, et al. “Structure and biological activity of endogenous and synthetic agonists of GPR119.” Russian Chemical Reviews, vol. 87, no. 2, Nov. 2017, pp. 151-166. https://rcr.colab.ws/publications/10.1070/RCR4737.
Views / Visits / Downloads
26 / 25 / 7

Abstract

A G-protein-coupled receptor, GPR119, is a promising pharmacological target for a new class of hypoglycaemic drugs with an original mechanism of action, namely, increase in the glucose-dependent incretin and insulin secretion. In 2005, the first ligands were found and in the subsequent years, a large number of GPR119 agonists were synthesized in laboratories in various countries; the safest and most promising agonists have entered phase I and II clinical trials as agents for the treatment of type 2 diabetes mellitus and obesity. The review describes the major endogenous GPR119 agonists and the main trends in the design and modification of synthetic structures for increasing the hypoglycaemic activity. The data on synthetic agonists are arranged according to the type of the central core of the molecules.

The bibliography includes 104 references.

References

1.
The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors
Alexander S.P., Davenport A.P., Kelly E., Marrion N., Peters J.A., Benson H.E., Faccenda E., Pawson A.J., Sharman J.L., Southan C., Davies J.A.
British Journal of Pharmacology , 2015
2.
rcr_87_2_151_bib2
Bakir
2006
4.
GPCRdb: an information system for G protein-coupled receptors
Isberg V., Mordalski S., Munk C., Rataj K., Harpsøe K., Hauser A.S., Vroling B., Bojarski A.J., Vriend G., Gloriam D.E.
Nucleic Acids Research , 2015
5.
rcr_87_2_151_bib5
Zhu
2013
6.
GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity
Overton H.A., Fyfe M.C., Reynet C.
British Journal of Pharmacology , 2008
7.
Receptors for acylethanolamides—GPR55 and GPR119
Godlewski G., Offertáler L., Wagner J.A., Kunos G.
Prostaglandins and Other Lipid Mediators , 2009
8.
Sustained wash-resistant receptor activation responses of GPR119 agonists
Hothersall J.D., Bussey C.E., Brown A.J., Scott J.S., Dale I., Rawlins P.
European Journal of Pharmacology , 2015
9.
rcr_87_2_151_bib9
Nunez
PLoS ONE , 2014
10.
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva F.K., Sposito A.C.
Cardiovascular Diabetology , 2014
12.
rcr_87_2_151_bib12
2010
13.
Peptide YY Is Critical for Acylethanolamine Receptor Gpr119-Induced Activation of Gastrointestinal Mucosal Responses
Cox H.M., Tough I.R., Woolston A., Zhang L., Nguyen A.D., Sainsbury A., Herzog H.
Cell Metabolism , 2010
14.
Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119
Engelstoft M.S., Norn C., Hauge M., Holliday N.D., Elster L., Lehmann J., Jones R.M., Frimurer T.M., Schwartz T.W.
British Journal of Pharmacology , 2014
15.
rcr_87_2_151_bib15
Zhang
PLoS ONE , 2013
16.
Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists
Matsuda D., Kobashi Y., Mikami A., Kawamura M., Shiozawa F., Kawabe K., Hamada M., Oda K., Nishimoto S., Kimura K., Miyoshi M., Takayama N., Kakinuma H., Ohtake N.
Bioorganic and Medicinal Chemistry Letters , 2016
17.
rcr_87_2_151_bib17
2002
18.
The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119
Stone V.M., Dhayal S., Smith D.M., Lenaghan C., Brocklehurst K.J., Morgan N.G.
British Journal of Pharmacology , 2012
20.
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., Di Marzo V.
Proceedings of the National Academy of Sciences of the United States of America , 1998
21.
rcr_87_2_151_bib21
Kang
Sci. Rep. , 2016
22.
Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells
Ning Y., O'Neill K., Lan H., Pang L., Shan L.X., Hawes B.E., Hedrick J.A.
British Journal of Pharmacology , 2008
23.
rcr_87_2_151_bib23
Shenoy
Int. J. Pharm. Sci. Res. , 2011
24.
rcr_87_2_151_bib24
Rivera
Front. Cell Neurosci. , 2015
25.
Glial Modulation by N-acylethanolamides in Brain Injury and Neurodegeneration
Herrera M.I., Kölliker-Frers R., Barreto G., Blanco E., Capani F.
Frontiers in Aging Neuroscience , 2016
27.
The G Protein‐Coupled Receptor 55 Ligand l ‐α‐Lysophosphatidylinositol Exerts Microglia‐Dependent Neuroprotection After Excitotoxic Lesion
Kallendrusch S., Kremzow S., Nowicki M., Grabiec U., Winkelmann R., Benz A., Kraft R., Bechmann I., Dehghani F., Koch M.
GLIA , 2013
29.
Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells
Hodge D., Glass L.L., Diakogiannaki E., Pais R., Lenaghan C., Smith D.M., Wedin M., Bohlooly-Y M., Gribble F.M., Reimann F.
Peptides , 2016
30.
N-Oleoyldopamine Enhances Glucose Homeostasis through the Activation of GPR119
Chu Z., Carroll C., Chen R., Alfonso J., Gutierrez V., He H., Lucman A., Xing C., Sebring K., Zhou J., Wagner B., Unett D., Jones R.M., Behan D.P., Leonard J., et. al.
Molecular Endocrinology , 2010
31.
Targeting GPR119 for the Potential Treatment of Type 2 Diabetes Mellitus
Mo X., Yang Z., Tao Y.
Progress in Molecular Biology and Translational Science , 2014
33.
rcr_87_2_151_bib33
Jones
Annu. Rep. Med. Chem. , 2009
34.
rcr_87_2_151_bib34
2007
35.
rcr_87_2_151_bib35
2008
36.
Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion
Yoshida S., Ohishi T., Matsui T., Shibasaki M.
Biochemical and Biophysical Research Communications , 2010
37.
The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function
Yoshida S., Ohishi T., Matsui T., Tanaka H., Oshima H., Yonetoku Y., Shibasaki M.
Diabetes, Obesity and Metabolism , 2010
38.
Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice
Yoshida S., Ohishi T., Matsui T., Tanaka H., Oshima H., Yonetoku Y., Shibasaki M.
Biochemical and Biophysical Research Communications , 2010
39.
Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice
Oshima H., Yoshida S., Ohishi T., Matsui T., Tanaka H., Yonetoku Y., Shibasaki M., Uchiyama Y.
Life Sciences , 2013
40.
Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists
Negoro K., Yonetoku Y., Misawa-Mukai H., Hamaguchi W., Maruyama T., Yoshida S., Takeuchi M., Ohta M.
Bioorganic and Medicinal Chemistry , 2012
41.
Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists
Zhang J.(., Li A., Yu M., Wang Y., Zhu J., Kayser F., Medina J.C., Siegler K., Conn M., Shan B., Grillo M.P., Eksterowicz J., Coward P., Liu J.(.
Bioorganic and Medicinal Chemistry Letters , 2013
42.
Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119
Wacker D.A., Wang Y., Broekema M., Rossi K., O’Connor S., Hong Z., Wu G., Malmstrom S.E., Hung C., LaMarre L., Chimalakonda A., Zhang L., Xin L., Cai H., Chu C., et. al.
Journal of Medicinal Chemistry , 2014
44.
rcr_87_2_151_bib44
Nunez
46.
Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice
Al-Barazanji K., McNulty J., Binz J., Generaux C., Benson W., Young A., Chen L.
Journal of Pharmacology and Experimental Therapeutics , 2015
47.
rcr_87_2_151_bib47
2008
48.
Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile
Semple G., Lehmann J., Wong A., Ren A., Bruce M., Shin Y., Sage C.R., Morgan M., Chen W., Sebring K., Chu Z., Leonard J.N., Al-Shamma H., Grottick A.J., Du F., et. al.
Bioorganic and Medicinal Chemistry Letters , 2012
49.
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes
Katz L.B., Gambale J.J., Rothenberg P.L., Vanapalli S.R., Vaccaro N., Xi L., Sarich T.C., Stein P.P.
Diabetes, Obesity and Metabolism , 2012
51.
Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119
Semple G., Fioravanti B., Pereira G., Calderon I., Uy J., Choi K., Xiong Y., Ren A., Morgan M., Dave V., Thomsen W., Unett D.J., Xing C., Bossie S., Carroll C., et. al.
Journal of Medicinal Chemistry , 2008
52.
GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion
Chepurny O.G., Holz G.G., Roe M.W., Leech C.A.
Molecular Endocrinology , 2016
53.
A Role for β-Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucose-Dependent Insulin Release
Leonard J., Behan D.P., Semple G., Demarest K., Liang Y., Unett D., Bagnol D., Mondala H., Gao H., Moloney M., Lucman A., Gutierrez V., Carroll C., He H., Jones R.M., et. al.
Endocrinology , 2007
54.
A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide Release
Chu Z., Carroll C., Alfonso J., Gutierrez V., He H., Lucman A., Pedraza M., Mondala H., Gao H., Bagnol D., Chen R., Jones R.M., Behan D.P., Leonard J.
Endocrinology , 2008
55.
rcr_87_2_151_bib55
2008
56.
rcr_87_2_151_bib56
2008
57.
rcr_87_2_151_bib57
2008
58.
rcr_87_2_151_bib58
2008
59.
rcr_87_2_151_bib59
2008
60.
rcr_87_2_151_bib60
2008
61.
rcr_87_2_151_bib61
2008
62.
rcr_87_2_151_bib62
2008
63.
rcr_87_2_151_bib63
2008
64.
rcr_87_2_151_bib64
Kim
J. Diabetes Res. , 2013
65.
Kim S., Kim D.H., Kim Y., Ha T., Yang J., Park S.H., Jeong K.W., Rhee J.
Biomolecules and Therapeutics , 2014
66.
A categorical structure–activity relationship analysis of GPR119 ligands
Kumar P., Carrasquer C.A., Carter A., Song Z., Cunningham A.R.
SAR and QSAR in Environmental Research , 2014
68.
Stimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor
Ansarullah, Lu Y., Holstein M., DeRuyter B., Rabinovitch A., Guo Z.
PLoS ONE , 2013
69.
Activation of GPR119 Stimulates Humanβ-Cell Replication and Neogenesis in Humanized Mice with Functional Human Islets
Ansarullah, Free C., Christopherson J., Chen Q., Gao J., Liu C., Naji A., Rabinovitch A., Guo Z.
Journal of Diabetes Research , 2016
70.
rcr_87_2_151_bib70
2008
71.
rcr_87_2_151_bib71
2008
72.
rcr_87_2_151_bib72
Roberts
73.
rcr_87_2_151_bib73
2008
74.
rcr_87_2_151_bib74
2008
75.
rcr_87_2_151_bib75
2008
76.
rcr_87_2_151_bib76
2008
77.
rcr_87_2_151_bib77
2008
79.
Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists
Gillespie P., Goodnow R.A., Saha G., Bose G., Moulik K., Zwingelstein C., Myers M., Conde-Knape K., Pietranico-Cole S., So S.
Bioorganic and Medicinal Chemistry Letters , 2014
80.
Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists
Wang Y., Yu M., Zhu J., Zhang J.(., Kayser F., Medina J.C., Siegler K., Conn M., Shan B., Grillo M.P., Liu J.(., Coward P.
Bioorganic and Medicinal Chemistry Letters , 2014
81.
Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
Yu M., (Ken) Zhang J., Wang Y., Zhu J., Kayser F., Medina J.C., Siegler K., Conn M., Shan B., Grillo M.P., Coward P., (Jim) Liu J.
Bioorganic and Medicinal Chemistry Letters , 2014
82.
Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists
Sato K., Sugimoto H., Rikimaru K., Imoto H., Kamaura M., Negoro N., Tsujihata Y., Miyashita H., Odani T., Murata T.
Bioorganic and Medicinal Chemistry , 2014
83.
Synthesis and biological evaluation of thienopyrimidine derivatives as GPR119 agonists
Jeon M., Lee K.M., Kim I.H., Jang Y.K., Kang S.K., Lee J.M., Jung K., Kumar J.A., Rhee S.D., Jung W.H., Song J.S., Bae M.A., Kim K.R., Ahn J.H.
Bioorganic and Medicinal Chemistry Letters , 2014
84.
Synthesis and structure–activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists
Ye X., Morales C.L., Wang Y., Rossi K.A., Malmstrom S.E., Abousleiman M., Sereda L., Apedo A., Robl J.A., Miller K.J., Krupinski J., Wacker D.A.
Bioorganic and Medicinal Chemistry Letters , 2014
85.
G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges
Ritter K., Buning C., Halland N., Pöverlein C., Schwink L.
Journal of Medicinal Chemistry , 2015
86.
rcr_87_2_151_bib86
2008
87.
rcr_87_2_151_bib87
2008
88.
Identification of New Potent GPR119 Agonists by Combining Virtual Screening and Combinatorial Chemistry
Wellenzohn B., Lessel U., Beller A., Isambert T., Hoenke C., Nosse B.
Journal of Medicinal Chemistry , 2012
89.
Conformational restriction in a series of GPR119 agonists: Differences in pharmacology between mouse and human
Scott J.S., Brocklehurst K.J., Brown H.S., Clarke D.S., Coe H., Groombridge S.D., Laber D., MacFaul P.A., McKerrecher D., Schofield P.
Bioorganic and Medicinal Chemistry Letters , 2013
90.
Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes
Xia Y., Chackalamannil S., Greenlee W.J., Jayne C., Neustadt B., Stamford A., Vaccaro H., Xu X.(., Baker H., O’Neill K., Woods M., Hawes B., Kowalski T.
Bioorganic and Medicinal Chemistry Letters , 2011
91.
Discovery of the oxazabicyclo[3.3.1]nonane derivatives as potent and orally active GPR119 agonists
Dai X., Stamford A., Liu H., Neustadt B., Hao J., Kowalski T., Hawes B., Xu X., Baker H., O’Neill K., Woods M., Tang H., Greenlee W.
Bioorganic and Medicinal Chemistry Letters , 2015
92.
AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes
Yoshida S., Tanaka H., Oshima H., Yamazaki T., Yonetoku Y., Ohishi T., Matsui T., Shibasaki M.
Biochemical and Biophysical Research Communications , 2010
93.
Synthesis and Biological Evaluation of a 6-Aminofuro[3,2–c]pyridin-3(2H)-one Series of GPR 119 Agonists
Sakairi M., Kogami M., Torii M., Kuno Y., Ohsawa Y., Makino M., Kataoka D., Okamoto R., Miyazawa T., Inoue M., Takahashi N., Harada S., Watanabe N.
Arzneimittelforschung , 2012
94.
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes
Liu P., Hu Z., DuBois B.G., Moyes C.R., Hunter D.N., Zhu C., Kar N.F., Zhu Y., Garfunkle J., Kang L., Chicchi G., Ehrhardt A., Woods A., Seo T., Woods M., et. al.
ACS Medicinal Chemistry Letters , 2015
95.
Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists
Azimioara M., Alper P., Cow C., Mutnick D., Nikulin V., Lelais G., Mecom J., McNeill M., Michellys P., Wang Z., Reding E., Paliotti M., Li J., Bao D., Zoll J., et. al.
Bioorganic and Medicinal Chemistry Letters , 2014
96.
rcr_87_2_151_bib96
2014
97.
Comparing hypoglycemic activity of novel GPR119 agonist and DPP-4 inhibitor sitagliptin
Tyurenkov I.N., Kurkin D.V., Bakulin D.A., Volotova E.V., Chafeev M.A.
Problemy Endokrinologii , 2016
98.
rcr_87_2_151_bib98
Tyurenkov
Experim. Clin. Pharmacol. , 2017
99.
Influence of novel GPR119 receptor agonist on plasma glucose and insulin level, as well as structural changes of pancreas islets in rats with experimental type 2 diabetes
Tyurenkov I.N., Kurkin D.V., Bakulin D.A., Volotova E.V., Smirnov A.V., Mednikov D.S., Shafeev M.A.
Problemy Endokrinologii , 2016
100.
ZB-16, a Novel GPR119 Agonist, Relieves the Severity of Streptozotocin–Nicotinamide-Induced Diabetes in Rats
Tyurenkov I.N., Kurkin D.V., Bakulin D.A., Volotova E.V., Chafeev M.A., Smirnov A.V., Morkovin E.I.
Frontiers in Endocrinology , 2017
102.
rcr_87_2_151_bib102
Zhang
Proc. Natl. Acad. Sci. USA , 2014
103.
rcr_87_2_151_bib103
2016
104.
rcr_87_2_151_bib104
Park
PLoS ONE , 2016